blog.aids.gov − NIAID
AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

NIAID

Historic HIV Vaccine Clinical Trial: Facebook Live with NIH’s Dr. Dieffenbach

Dr. Carl Dieffenbach on Facebook Live from Cape Town, South Africa

In a Facebook Live interview from Cape Town, South Africa earlier this week, we heard from NIH’s Dr. Carl Dieffenbach about the exciting launch of HVTN 702, a new HIV vaccine clinical trial supported by NIH. The first HIV vaccine efficacy study to launch anywhere in seven years, HVTN 702 is testing whether an experimental…

NIH Statement on World AIDS Day 2016

nih-logo-resized-nov-2016

This year, the world marked the 35th anniversary of the first published reports of what would come to be known as HIV/AIDS. This disease has wrought enormous suffering and devastation and caused more than 35 million deaths. Yet today, thanks to remarkable achievements in biomedical science and public health, we have the tools to build…

Watch HIV Vaccine Trial Launch in South Africa Via Facebook Live! This Wednesday!

niaid-fauci-quote-for-hvtn-702-blog-resized-nov-2016

Director’s Note, Office of HIV/AIDS and Infectious Disease Policy, HHS: Scientific advances have given us the tools we need to end new HIV infections and save lives. But our work is not yet done, either here in the U.S. or around the world. As we approach the observance of World AIDS Day on December 1…

NIH Spotlights HIV Cure Research

anne-and-carl-fb-live-nov-15-2016-resized

In two Facebook Live events from NIAID’s Strategies for an HIV Cure conference this week we learned about advances in HIV cure research from leaders in HIV science. Dr. Fauci Reflects on the State of HIV Cure Research As the third biennial conference got underway on the NIH campus in Bethesda, Maryland, we had the…

NIH’s Dr. Carl Dieffenbach Discusses Viral Suppression

viral-supression-video-diffenbach-featured-imagenresized-nov-2016

Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), has spoken with AIDS.gov about the important issue of viral suppression at several major HIV conferences during the past few months, including the HIV Research for Prevention (R4P) Conference in Chicago, the 2016 Ryan White Conference in Washington, DC,…

ICYMI – Advances in Research on HIV Prevention for Women

carl-and-anne-fb-live-hivr4p-resized-oct-2016

Last week, in a Facebook Live event we heard from NIH’s Dr. Carl Dieffenbach about some new developments in HIV prevention for women shared at the HIV Research for Prevention Conference  (R4P) in Chicago.  Carl is the Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases. He and his…

Large Increases in HIV Suppression Needed to Reduce New Infections in Critical Population

NIAID image for Oct 20 blog - HIV on a T cell - resized

NIH-Funded Study Aims to Identify and Treat HIV-Infected Men Who Have Sex With Men Achieving moderate reduction of new HIV infections among men who have sex with men (MSM) will depend on significantly increasing the percentage of HIV-infected MSM whose viral load is suppressed to undetectable levels, according to a new mathematical model based on…

Women Report Vaginal Ring for Preventing HIV Had Little Effect on Sexual Intercourse

NIAID vaginal ring blog image - Oct 19 - resized

Violence and Social Harm Were Associated with Low Adherence Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear. This finding is among several insights gleaned about experiences of women who used the…